Ebara with its specialties in fluid technology, biotechnology, and nanotechnology, has devoted many resources to research and development of life science technology and brought it to stage where practical applications are now possible. Ebara proposes new nano Drug Delivery System technologies that differ from previous concepts.The purpose of the Drug Delivery System, or DDS, is to promptly treat only the affected area and eliminate side-effects by delivering the drug to the target site in the body with the right amount of drug at the right time. Among the various DDS technologies proposed up to the present, nanoparticle delivery technologies have drawn wide attention.These technologies aim to prevent side-effects by making poorly soluble drugs soluble in order to reduce dosage amounts while maintaining efficacy and providing immediate or persistence effects by controlling the release rate of the drug in the body.To put nano DDS technologies featuring these excellent characteristics into practical use, Ebara proposes a series of creative and effective platform technologies called ESNAP.

ESNAP^TM DDS platform

ESNAP^TM-C formulation

	Build up process by pegylated nano carrier particle;100 to 200nm uniform size Surfactant free process 10 to 30 wt% drug loading ratio
ESNAPTM-L formulation
	Break down process by laser ablation;50 to 200nm uniform size Surfactant free process 100 wt% nano drug particle
ESNAPTM-S formulation
	Build up process by micro fluidics technology;100 to 200nm uniform size Surfactant free process 100 wt% nano drug particles

Dramatic effect of ESNAP ^TM Technology

in-vivo test result of Itraconazole by ESNAPTM-C
	Process: ESNAPTM-C Drug: Itraconazole Itraconazole formulated by ESNAPTM-C shows more than hundred times better plasma concentration than API.
in-vivo test result of SN-38 by ESNAPTM-L
	Process: ESNAPTM-L Drug: SN-38 SN-38 formulated by ESNAPTM-L shows better tumor inhibition rate than its pro-drug CPT-11
in-vivo test result of drug X by ESNAPTM-S
	Process: ESNAPTM-S Drug: drug X Drug X formulated by ESNAPTM-S shows better plasma concentration than its market released drug